Promising new combo therapy targets tough childhood cancer
NCT ID NCT07537400
First seen Apr 19, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This study tests whether adding the drug naxitamab to standard chemotherapy is safe and effective for children and young adults with high-risk neuroblastoma, an aggressive nerve cancer. Ten newly diagnosed patients will receive the combination and be monitored for side effects and tumor response. The goal is to improve treatment outcomes for this hard-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK NEUROBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shaare Zedek Medical Center
Jerusalem, Israel
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.